<DOC>
	<DOCNO>NCT00440388</DOCNO>
	<brief_summary>This phase II clinical trial patient receive systemic treatment follicular non-Hodgkin 's lymphoma . The study combine rituximab , approve drug disease , AT-101 , experimental drug . The hypothesis add AT-101 rituximab regimen , improvement patient ' response treatment observe verse rituximab alone .</brief_summary>
	<brief_title>Safety &amp; Efficacy Study AT-101 Combination w/ Rituximab Previously Untreated Grade I-II Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Further Study Details provide Ascenta .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Gossypol acetic acid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Gossypol</mesh_term>
	<criteria>Histologically confirm , previously untreated Grade III follicular Bcell nonHodgkin 's lymphoma ( stage I , II , III IV ) . Patients may receive radiation therapy one lymph node region ; Stage I II patient must relapse prior radiation therapy eligible ; Patients FLIPI score may participate . Patients FLIPI score 35 may enrol asymptomatic disease , without worsen disease disease relatedsymptoms ; however patient FLIPI score 02 must evidence worsen disease ; ECOG performance status 01 ; Measurable disease ; Adequate hematological function indicate : Absolute neutrophil count ( ANC ) &gt; 1,000/µL ; +Hemoglobin &gt; 8 g/dL ( It acceptable transfuse PRBC achieve criterion ) ; Platelet count &gt; 50 x 109/L . Adequate hepatic renal function indicate : Serum creatinine ≤2.0 mg/dL ; Serum albumin ≥2.5 g/dL ; Total bilirubin ≤1.5 x upper limit normal ( ULN ) ; Serum AST ALT ≤1.5 x ULN . Able swallow retain oral medication Patients severe lymphomarelated symptom require rapid response therapy ( e.g. , requirement cytoreduction due advance disease organ compromise , respiratory compromise large effusion airway obstruction , bowel obstruction , ureteral obstruction , chylous ascites ) ; Active symptomatic fungal , bacterial and/or viral infection include , limited active HIV viral hepatitis ( A , B C ) ; History hepatitis B infection ; Any Bcell , Tcell transform lymphoma histologically confirm follicular nonHodgkin 's lymphoma ; Central nervous system ( CNS ) lymphoma , CNS leptomeningeal involvement lymphoma ( treated remission ) , HIVrelated lymphoma , patient symptoms suggest HIV infection ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>cancer</keyword>
	<keyword>lymphoma</keyword>
	<keyword>Non-Hodgkin 's</keyword>
	<keyword>Non-Hodgkins</keyword>
	<keyword>AT-101</keyword>
	<keyword>AT101</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Rituximab</keyword>
</DOC>